Literature DB >> 19150298

Endovenous laser ablation and sclerotherapy for treatment of varicose veins.

Natasha Brasic1, David Lopresti, Hugh McSwain.   

Abstract

Superficial venous insufficiency is a common problem associated with varicose veins. Venous insufficiency and varicose veins can be symptomatic, but more commonly they are a cosmetic concern. In this article, we discuss the relevant anatomy and pathophysiology of superficial venous insufficiency, review the current literature for varicose vein treatment, and cover the technical aspects of diagnosing and treating superficial venous insufficiency. Saphenofemoral junction incompetence with resultant greater saphenous vein reflux is the most common cause of varicose veins; because this condition constitutes the majority of patients encountered in practice, we will concentrate on this area. Endovenous laser ablation and sclerotherapy are covered, including patient workup and selection, procedure set-up, and anesthesia.

Entities:  

Mesh:

Year:  2008        PMID: 19150298     DOI: 10.1016/j.sder.2008.08.001

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  5 in total

1.  A rare complication of endovenous laser ablation: intravascular laser catheter breakage.

Authors:  Orhan Bozoglan; Bulent Mese; Mehmet Fatih Inci; Erdinc Eroglu
Journal:  BMJ Case Rep       Date:  2013-03-18

2.  Vascular sclerosing effects of bleomycin on cutaneous veins: a pharmacopathologic study on experimental animals.

Authors:  Khalid M AlGhamdi; Ashok Kumar; Abdelkader E Ashour; Ammar C Al-Rikabi; Abdullah Hasan AlOmrani; Shaik Shaffi Ahamed
Journal:  An Bras Dermatol       Date:  2017 Jul-Aug       Impact factor: 1.896

3.  Endovascular laser therapy for varicose veins: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2010-04-01

4.  Endovascular radiofrequency ablation for varicose veins: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2011-02-01

5.  Phenol as a novel sclerosing agent: A safety and efficacy study on experimental animals.

Authors:  Khalid M Alghamdi; Abdelkader E Ashour; Ammar C Rikabi; Noura A Moussa
Journal:  Saudi Pharm J       Date:  2013-02-10       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.